Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With Acute Myeloid Leukemia
NCT06744556Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2025; status: active, not recruiting.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06744556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744556.